A SCORING METHOD FOR AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE THERAPY

    公开(公告)号:WO2022054009A2

    公开(公告)日:2022-03-17

    申请号:PCT/IB2021/058273

    申请日:2021-09-11

    Abstract: A method for predicting how a cancer patient will respond to an antibody drug conjugate (ADC) therapy involves computing a predictive response score based on single-cell ADC scores for each cancer cell. The ADC includes an ADC payload and an ADC antibody that targets a protein on each cancer cell, wherein the protein is human epidermal growth factor receptor 2 (HER2). A tissue sample is immunohistochemically stained using a dye linked to a diagnostic antibody that binds to the protein on cancer cells in the tissue sample. Cancer cells in a digital image of the tissue are detected. For each cancer cell, a single-cell ADC score is computed based on the staining intensities of the dye in the membrane and/or cytoplasm of the cancer cell and/or in the membranes and cytoplasms of neighboring cancer cells. The response of the cancer patient to the ADC therapy is predicted by aggregating all single-cell ADC scores of the tissue sample using a statistical operation.

Patent Agency Ranking